BBH - ETF AI Analysis

Top Page

VanEck Biotech ETF (BBH)

Rating:72Outperform

Price Target:―

BBH, the VanEck Biotech ETF, has a solid overall rating driven mainly by large positions in leaders like Amgen and Gilead Sciences, which benefit from strong financial performance, positive earnings call sentiment, and well-positioned drug portfolios. Additional support comes from innovative names such as Vertex, Regeneron, and Argenx, which combine robust revenue growth with promising pipelines, though often at high valuations. The main drawbacks are weaker holdings like Insmed, which faces profitability and cash flow issues, and the overall concentration in the biotech sector, which can increase volatility and sensitivity to drug development and regulatory news.

Positive Factors

Focused Biotech Exposure

The fund is heavily invested in health care and biotechnology companies, giving investors targeted access to this specialized growth area.

Leading Large-Cap Holdings

Top positions like Amgen and Gilead Sciences have shown steady gains this year, helping support the ETF’s overall performance.

Moderate Expense Ratio

The fund’s expense ratio is relatively moderate for a specialized biotech ETF, which helps investors keep more of their returns over time.

Negative Factors

High Stock Concentration

A small number of holdings make up a large share of the portfolio, increasing the impact that any one company’s moves can have on the fund.

Several Weak Top Holdings

Some of the larger positions, such as Vertex, Regeneron, Alnylam, and Insmed, have shown weak performance this year, which can drag on returns.

Limited Diversification

With almost all assets in U.S. health care stocks, the ETF offers little protection if the biotech sector or U.S. market faces a downturn.

BBH vs. SPDR S&P 500 ETF (SPY)

AUM381.03M

RegionGlobal

Expense Ratio0.35%

Beta0.65

IssuerVanEck

Inception DateDec 20, 2011

Dividend Yield0.5%

Asset ClassEquity

Index TrackedMVIS US Listed Biotech 25

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume6,839

30 Day Avg. Volume8,513

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

218.86

Price Target Upside― Downside

Rating ConsensusStrong Buy

Number of Analyst Covering25

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

BBH Summary

The VanEck Biotech ETF (BBH) tracks the MVIS US Listed Biotech 25 Index and focuses on U.S. biotechnology companies within the health care sector. It holds well-known names like Amgen and Gilead Sciences, along with smaller biotech firms working on new drugs, genetic research, and medical technologies. Someone might invest in BBH to seek long-term growth from medical breakthroughs and to get diversified exposure to many biotech companies in a single investment. However, biotech stocks can be very volatile, so the ETF’s price can swing sharply and may go up or down more than the overall market.

How much will it cost me?The VanEck Biotech ETF (BBH) has an expense ratio of 0.35%, meaning you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused ETF that targets biotechnology companies, which often require more active management to track this specialized market. It’s important to consider whether the potential growth in this niche sector aligns with your investment goals.

What would affect this ETF?The VanEck Biotech ETF (BBH) could benefit from advancements in biotechnology, such as breakthroughs in drug development and genetic research, as well as increased global demand for innovative health solutions. However, it may face challenges from regulatory hurdles, high research costs, and potential economic downturns that could impact funding for biotech companies. Additionally, changes in interest rates could affect the financial performance of its top holdings like Gilead Sciences and Amgen.

BBH Top 10 Holdings

BBH is a pure biotech play, and its story starts with heavyweights Amgen and Gilead, which have been steady to slightly rising over the past few months and help anchor the fund’s performance. Mid-sized leaders like Vertex and Regeneron have seen more mixed trading, recently losing a bit of steam after earlier gains. On the weaker side, Alnylam and Insmed have been lagging, acting as a brake on returns. With nearly all exposure in health care and a global biotech tilt, this ETF lives and dies by drug pipelines and clinical trial headlines.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
GILD	Gilead Sciences	17.56%	$66.94M	$188.35B	45.86%	78 Outperform
AMGN	Amgen	16.67%	$63.54M	$197.19B	25.77%	77 Outperform
VRTX	Vertex Pharmaceuticals	9.24%	$35.22M	$117.98B	1.31%	78 Outperform
REGN	Regeneron	7.75%	$29.53M	$82.83B	16.34%	78 Outperform
ARGX	Argenx Se	4.62%	$17.61M	$51.64B	30.36%	79 Outperform
NTRA	Natera	3.83%	$14.61M	$28.75B	19.86%	73 Outperform
ONC	BeOne Medicines	3.57%	$13.60M	$43.00B	50.06%	61 Neutral
BIIB	Biogen	3.46%	$13.20M	$28.69B	42.36%	74 Outperform
INSM	Insmed	3.42%	$13.03M	$31.17B	84.30%	43 Neutral
ALNY	Alnylam Pharma	3.39%	$12.91M	$40.75B	20.29%	60 Neutral

BBH Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

193.55

Positive

100DMA

186.24

Positive

200DMA

171.41

Positive

Market Momentum

MACD

0.45

Positive

RSI

49.95

Neutral

STOCH

32.49

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 196.48, equal to the 50-day MA of 193.55, and equal to the 200-day MA of 171.41, indicating a neutral trend. The MACD of 0.45 indicates Positive momentum. The RSI at 49.95 is Neutral, neither overbought nor oversold. The STOCH value of 32.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBH.

BBH Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
BBH	―	―	$381.03M	0.35%	―
IVES	―	―	$961.01M	0.75%	―
JETS	―	―	$941.84M	0.60%	―
BUG	―	―	$884.38M	0.51%	―
NUKZ	―	―	$832.60M	0.85%	―
CANC	―	―	$151.35M	0.75%	―

Performance Comparison

BBH

VanEck Biotech ETF

195.12

34.56

21.52%

IVES

Dan IVES Wedbush AI Revolution ETF

―

JETS

U.S. Global Jets ETF

―

BUG

Global X Cybersecurity Etf

―

NUKZ

Range Nuclear Renaissance Index ETF

―

CANC

Tema Oncology ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents